Tiragolumab is a monoclonal antibody that targets the inhibitory receptor T-cell immunoglobulin and ITIM domain (TIGIT), which is expressed on lymphocytes and suppresses the immune response to cancer.
Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region and is thought to work as an immune amplifier with other cancer immunotherapies, based on preclinical research.
